GSK Announces Major Investment in US Supply Chain and R&D

Following US President Donald Trump's historic second state visit to Britain to finalize investment agreements, GSK announced on Wednesday that it intends to invest $30 billion in supply chain infrastructure and research and development in the US over the next five years.

The company said its new facilities will "bridge R&D and manufacturing across both the US and UK, strengthening the two countries' leadership in life sciences". According to London-based GSK, the investment includes $1.2 billion for the building of a new factory in Upper Merion, Pennsylvania, which will start construction in 2026 and develop new medications for cancer and respiratory conditions.

Along with better device and auto-injector assembly, new drug ingredient manufacturing capabilities, and AI and advanced digital technology skills, it will also invest in GSK's current five manufacturing facilities in the nation.

Also Read: GST reforms a step towards Atmanirbhar Bharat: Piyush Goyal

 As Trump looks to increase domestic production and threatens to impose import duties on the industry, GSK is the most recent pharmaceutical company to expand its presence in the US. Historically, trade disputes have not affected this sector.

"This landmark investment will create tens of thousands of American jobs and ensure that critical medicines and technologies are developed and manufactured right here on US soil”where they belong," US Commerce Secretary Howard Lutnick said.

According to the company, the $30 billion investment will strengthen R&D and clinical trial activities and the US is likely to rank first for the number of GSK studies, sites and clinical trials participants over the next five years.